JL, re FDA
I listed to entire event, the FDA was very clear they were in possession of new science, and I believe they are not going to approve Vascepa. All studies on lipid lowering failed to produce reduction of CV events
I understand you point, but they have their backs covered on this one.
Amarin now have their backs up against the wall. I cant see anyone investors hanging 3+ years hoping for JELIS type results
major dilution coming - or a fire sale on business, hard to value now with meager sales and not enough cash . Easy pickings for BP to come along and get it cheap
Holding thru for December approval ? Sounds suicidal
FDA was clear about what to vote on- it was about guessing on reduce it, not Anchor actual data
News 
Market Data 
Discover 
